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Background:GeneralisedAnxietyDisorder (GAD) is a highprevalence, chronic disorder that can be treated effective-
ly through a number of web-based programs. However, online web programs for GAD have not been compared to
standard pharmacological treatment. The present study compares an Internet Intervention (Active Website) for
GAD and a selective serotonin re-uptake inhibitor (SSRI) (Sertraline), with an online attention placebo condition
(Control Website).
Objective: To evaluate the effectiveness of a web-based intervention for GAD in comparison to standard antidepres-
sant medication and an online attention placebo condition over a 10 week period, and with a follow-up at 6 and at
12 months.
Methods: The studywaspart of a larger scale preventionprogram. 152people aged18–30 yearswhomet the criteria
for GAD on the MINI received referrals to the treatment sub-study. The primary outcome was anxiety symptoms
measured by the Generalised Anxiety Disorder 7-item Scale (GAD-7), and the secondary outcome was depression
measured by the Center for Epidemiologic Studies Depression Scale (CES-D).
Results: There was very poor uptake to the trial (around 14% of those referred). However, even in this small sample,
Sertraline compared to the ControlWebsitewas signiﬁcant at post-test and 6 months, and the Internet Intervention
was signiﬁcant at post-test. Relative to the ControlWebsite condition at post-test, for the GAD-7 and CES-D respec-
tively, the between group effect sizes were d= 2.43 and d= 0.68 for the Active Website condition, and 3.00 and
0.20 for the Sertraline condition. The within group effect size for the Control Website from baseline to post-test
was−0.04 for the GAD-7 and 0.31 for CES-D respectively.
Conclusions: The ﬁndings will need to be extended and conﬁrmed in a larger trial. However, they do suggest that
both standard pharmacological treatment and online interventions forGADare effective in sampleswith a diagnosis
of GAD recruited via online methods. The low rate of engagement for face-to-face treatment by those who opt ﬁrst
for a web program suggests that treatment preferences are important in help-seeking.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Generalised Anxiety Disorder (GAD) is a high prevalence (Johansson
et al., 2013), chronic disorder that can be treated through the web
(Christensen et al., 2014a). Web-based interventions have high accept-
ability, are accessible, engaging and effective. Indeed, ﬁve meta-analyses
published since 2009 (Andersson and Cuijpers, 2009; Andrews et al.,l Road, Prince ofWales Hospital,
tensen).
. This is an open access article under2010; Cuijpers et al., 2009; Grifﬁths et al., 2010b; Lewis et al., 2012) con-
ﬁrm the effectiveness of online interventions for anxiety. For GAD in par-
ticular, strong evidence has emerged for online cognitive behavioural
therapy (iCBT) (Mewton et al., 2012; Robinson et al., 2010; Spence
et al., 2011). Psychodynamic online interventions have also been found
to be effective (Andersson et al., 2012). Sertraline, along with the SSRIs
escitalopram and paroxetine, is a ﬁrst-line pharmacologic treatment for
GAD (Baldwin and Polkinghorn, 2005). Randomised, placebo controlled
trials have found Sertraline efﬁcacious for GAD in adults (Allgulander
et al., 2004; Brawman-Mintzer et al., 2006), children and adolescents
(Rynn et al., 2001;Walkup et al., 2008) over 9 to 12 weeks, and Sertralinethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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edge, a direct comparison of online therapy to a standardpharmacological
intervention has not yet been reported for GAD.
We undertook a treatment trial comparing an online program (Active
Website) with SSRI/antidepressant medication (Sertraline), and a control
condition (Control Website). Participants were recruited to the trial after
they were excluded from the primary prevention trial, an exclusion that
was based on theirmeeting criteria forGADduring adiagnostic interview.
Participants were randomised to one of three conditions: Active Website
offering iCBT, Sertraline, or a Control Website. Regardless of randomised
condition, all participants were assessed and monitored by medical staff
during the course of the trial.
2. Methods
2.1. Study design
The study was a randomised controlled trial of young adults recruit-
ed from the Electoral Roll, who were excluded from a prevention trial
(Christensen et al., 2014b), but invited to participate in a treatment
trial. The study consisted of a 10 week treatment phase and a
12 month follow-up phase, with measures administered at screening,
baseline, post-test, and 6 and 12 months after post-test. Unlike the pre-
vention trial, treatment required face-to-face assessment and monitor-
ing. The study received ethics approval from The University of Sydney
(11-2009/12091) and The Australian National University (2008/548)
Human Research Ethics Committees.
2.2. Study population
Adults, aged 18–30 years with a primary anxiety diagnosis of
GAD formed the study population. Inclusion criteria included a
GAD diagnosis based on the Anxiety Disorders Interview Schedule
for DSM-IV (ADIS-IV) criteria (Brown, DiNardo, & Barlow, 1994;
Sheehan et al., 1998), informed consent, access to the internet, active
email address and phone number, sufﬁcient English, willingness to
attend face-to-face assessment at an inner city medical clinic at-
tached to a University, and willingness to take antidepressant medi-
cation and to be monitored over 12 weeks. Exclusion criteria
included current undertaking of cognitive behaviour therapy (CBT)
with a health professional, current treatment with a psychologist
or psychiatrist, risk of self-harm, psychosis, bipolar disorder, a pri-
mary diagnosis of depression, prior treatment with Sertraline, treat-
ment with monoamine oxidase inhibitors (MOAIs), or planned
pregnancy.
2.3. Recruitment procedure
A survey was sent to 120,000 randomly selected individuals aged
18–30 who were registered on the Australian Electoral Roll and located
in oneofﬁve Sydney electorates (Fig. 1). Of these, 12,400 returned ques-
tionnaires, 4205 were eligible based on a score greater than 4 on the
GAD-7 (Spitzer et al., 2006), and 1687 went on to complete the MINI
via phone. Informed consent for the screening survey was provided in
writing. Informed consent for the telephoneMINI was provided verbal-
ly. Informed consent for the intervention study was provided in writing
and in person at theﬁrst face-to-facemeeting. Postgraduate clinical psy-
chology students administered the telephone MINI interviews, and
were blind to the participant responses to the screening survey. Inter-
viewers were given 4 h of training, including practice interviews, with
oversight froma clinical psychologist and the research team. The 152 in-
dividuals who met the criteria for GAD on the MINI interview were of-
fered a referral to the treatment trial at the Brain and Mind Research
Institute (BMRI), University of Sydney. Participants then completed fur-
ther questionnaires, the ADIS-IV, and underwent amedical consultation
with a general practitioner (GP) to ascertain suitability for Sertraline.The ADIS-IV interviews were conducted by registered psychologists lo-
cated at the Brain and Mind Research Institute. A total of 21 (13.9%)
completed baseline and were randomised.
2.4. Baseline and randomisation
Randomisation occurred immediately after the baseline completion,
using existing automated web-based software developed by the inves-
tigators. In accordancewith ICH Guideline E9 (Lewis, 1999), the staff re-
sponsible for establishing randomisation procedures were not involved
in the day-to-day conduct of the trial. Further, no staff members in-
volved in the day-to-day running of the trial (i.e. not blind to group
membership) were involved in conducting follow-up assessments.
The research staff were not aware of group membership during the
baseline assessments as randomisation occurred after this stage.
2.5. Online programs
2.5.1. Active Website
The version of the E-couch website (e-couch@anu.edu.au) used in
the current study was divided into 10 modules, completed over the
10 week intervention period. The website comprises four sections in-
cluding psychoeducation, cognitive behaviour therapy, relaxation and
physical activity. The psychoeducation section (Modules 1 and 2) pro-
vides information on worry, stress, fear and anxiety; a description of
anxious thinking; differentiation of GAD from other anxiety disorders;
risk factors for GAD; comorbidity; and consequences of anxiety and
available treatments. This section is based on interventions for mental
health literacy that have succeeded in reducing symptomsof depression
and anxiety, and improving mental health attitudes (McIntosh et al.,
2004). The CBT toolkits (Modules 3–7) addressed typical anxious
thoughts and included sections on dealing with the purpose andmean-
ing of worry, the act of worrying and the content of worry. The informa-
tion is derived from materials that have been found to reduce anxious
cognitions in at-risk people (Kenardy et al., 2003, 2006). Progressive
muscle relaxation (PMR) (Module 8) instructs participants on how to
progressively tense and relax different muscle groups to induce relaxa-
tion and help to identify tension early. PMR has been trialled in a previ-
ous website program for depression in adults (Christensen et al., 2004)
and adolescents (Calear et al., 2009). Themindfulness meditation mod-
ule (Module 9) helps participants become aware of their breathing and
body, acknowledging thoughts and external distractions but remaining
focused on the present. The ﬁnal module, physical activity (Module 10),
tailors advice about physical activity based on the stages of change the-
ory (Prochaska and DiClemente, 1983).
2.5.2. Control Website
HealthWatch is an online programdeveloped for theANUWellBeing
study (Grifﬁths et al., 2010a). As implemented in the current study, the
program provided information about various health topics each week
for 10 weeks. These covered environmental health, nutrition myths,
heart health, activity,medication, the effects of temperature, oral health,
blood pressure and cholesterol, calcium, and back pain. Participants are
also asked to respond to a number of questions about potential risk fac-
tors for anxiety. In a recent trial conducted by the Australian National
University, HealthWatchwas not associatedwith a reduction in anxiety
or depressive symptoms over time, conﬁrming its value as an attention
placebo condition (Grifﬁths et al., 2012).
2.6. Components of trial conditions during intervention phase
All participants, regardless of condition, were provided with the
same amount of exposure to the clinical team of psychologists and gen-
eral practitioners (GPs). Speciﬁcally, all trial participants had scheduled
appointments with a psychologist in weeks 1, 2, 5 and 10 to monitor
progress and symptoms, and each participant was reviewed by a GP in
12,430 (10.4%) surveys 
returned
• 579 (4.7%) not in appropriate 
age range (18-30)
• 627 (5.0%) currently undergoing 
cognive behavioural therapy
• 1,229 (9.9%) currently seeing a 
psychiatrist or psychologist
• 139 (1.1%) no internet access at 
home or work 
• 6,884 (55.4%) few symptoms of 
generalized anxiety (GAD-7 score 
<5) 
2,517 (59.9%) consenng 
parcipants
830 (33.0%) unreachable by 
phone for MINI interview 
within 21 days1,687 (67.0%) completed 
MINI
4,205 (33.8%) eligible 
parcipants
120,000 surveys sent
107,570 surveys not returned
• 1,414 (33.6%) no consent to 
follow up
• 274 (6.5%) insuﬃcient 
contact informaon
21 (13.8%) completed 
baseline assessment, 
randomized
1409 ineligible – no current 
GAD
126 ineligible – current social 
phobia, panic disorder, PTSD 
or suicidality
7 (33.3%) 
Control website
8 (38.1%) 
Acve website
6 (28.6%) 
SSRI
6 (85.7%) 
Control website
post-test
6 (75.0%) 
Acve website
post-test
3 (50.0%) 
SSRI 
post-test
4 (57.1%) 
Control website
6 month
5 (62.5%)
Acve website
6 month
4 (66.7%)
SSRI
6 month
4 (57.1%) 
Control website
12 month
6 (75.0%) 
Acve website
12 month
1 (16.7%)
SSRI
12 month
152 (9.0%) eligible for 
clinical assessment
63 did not complete clinical 
assessment
28 did not sasfy the 
appropriate inclusion and 
exclusion criteria
40 did not consent to parcipate
Fig. 1. Study ﬂow. SSRI = Sertraline.
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SSRI medication condition. These review sessions across conditions en-
sured matching for clinician/GP involvement across interventions, and
active monitoring of health symptoms.
2.7. Online program conditions
In addition to the clinical team involvement, participants completed
the 10 week Active Website or Control Website at their home or ofﬁce
outside of the clinic environment. Modules took between 30 and
60 min to complete and were deployed weekly. During face-to-face
monitoring sessions in weeks 1, 2, 5 and 10, the psychologist encour-
aged use of the website but did not elaborate therapeutically. Partici-
pants in the Active Website condition were permitted to continue
using the program after the 10 week intervention period through the
public access portal.
2.8. SSRI medication condition
Participants were prescribed Sertraline for 10 weeks by the GP. Ser-
traline treatment was initiated at a daily dose of 25 mg which was in-
creased to 50 mg/day after one week with good tolerability (i.e. no
signiﬁcant side effects). After four weeks at a daily dose of 50 mg,participants with insufﬁcient clinical response but good tolerability
(i.e. no signiﬁcant side effects) were permitted to increase their dose
to a maximum of 100 mg/day. Sufﬁcient clinical response was deﬁned
as a Clinical Global Impression Global Improvement score of 1 (Very
much improved) or 2 (Much improved) (Guy, 1976). To monitor for
any additional or augmented side effects which might have resulted
due to this increased dosage, psychologists telephoned all trial partici-
pants during week 6 (to match for clinician contact), with additional
GP appointments arranged if necessary. If participants experienced
side effects that were distressing, or of which the nature and/or severity
were not consistent with existing Product Information, they were with-
drawn from the trial and offered alternative treatment. At the end of the
10 week intervention period, participants who had responded to treat-
ment were given the option of continuing Sertraline either under the
care of GPs at our themedical clinic or through a GP of their own choice.2.9. Primary outcome measures
The primary outcomemeasurewas the level of anxiety symptoms as
indexed by scale scores on the GAD-7 (Dear et al., 2011; Spitzer et al.,
2006) (a continuousmeasure). An additional outcomewas the achieve-
ment of a reduction of at least 20% on this scale (a binary score).
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not used due to small numbers of completers.2.10. Secondary outcome measures
The secondary outcome measure was depression as measured by
the Centre for Epidemiological Studies Depression Scale (CES-D)
(Radloff, 1977). Psychologists' ratings of response to treatment were
also assessed using the Clinical Global Impression (CGI) rating scale
(Guy, 1976).2.11. Power
The GAD treatment trial aimed to recruit 120 participants (40 per
group). However, only 21 participants were recruited, and power was
restricted. Nevertheless, the present study had 88% power with these
numbers to ﬁnd effect sizes greater than 2 between the active and con-
trol conditions at post-test.2.12. Statistical analyses
Given the low numbers recruited to our trial, and in contrast to our
planned analyses, only two comparisons were undertaken. These were
between Active Website vs Control Website and between Sertraline
and the Control Website. The senior trial biostatistician was blinded to
treatment group status. The GAD-7 and the CES-D data were collected
blindly through the web-portal without clinician input. Primary effec-
tiveness analyses were undertaken on an intention-to-treat basis.
Relative risk was calculated and tested for signiﬁcance for categori-
cal outcomes (achieving a 20% reduction in symptoms and the absence
of DSM-IV GAD diagnoses). These outcomes were also expressed in
terms of number needed to treat. Mixed effects repeated measures
models estimated the effect of the intervention on anxiety and depres-
sion scores over time. These models use an intention-to-treat approach,
assuming that data are missing at random. An unstructured variance–
covariance matrix was assumed, with degrees of freedom estimated
using Satterthwaite's correction.3. Results
3.1. Participants
Of the 21 participants randomised, 8 were assigned to the Active
Website, 6 to Sertraline, and 7 to the Control condition. Fig. 1 shows
the ﬂow of participants. Sample characteristics are presented in Table 1.3.2. Dropout
Dropout rates are presented in Fig. 1. Dropout was greatest in the
Sertraline condition, followed by the Control Website and least by the
Active Website condition. These differences were not signiﬁcant.Table 1
Characteristics of the sample at baseline by trial arm.
Active Website
(n = 8)
SSRI
(n = 6)
Control
(n = 7)
F or χ2 p
Mean (SD)
or %
Mean (SD)
or %
Mean (SD)
or %
Age 25.0 (4.2) 23.4 (4.0) 26.0 (3.8) 0.61 0.56
% female 75 83 86 0.31 0.86
GAD-7 anxiety 11.5 (3.7) 14.8 (5.2) 11.7 (4.8) 1.12 0.35
CESD depression 23.4 (11.7) 37.0 (12.0) 27.1 (7.6) 2.92 0.083.3. Anxiety
Based on the mixed effects repeated measures model, there was a
signiﬁcant reduction in symptoms overall across the 12 month period
(F= 27.9, df=3, 7.4, pb 0.001),withGAD-7 scores for thewhole sample
decreasing from 12.5 (SD=4.5) to 7.9 (SD=5.4) at post-test, 7.3 (SD=
4.9) at 6 months and4.7 (SD=3.6) at 12 months. Therewas a signiﬁcant
conditionby time interaction (F=5.7, df=6, 7.6, p= 0.016), reﬂecting a
signiﬁcant difference between Sertraline and the ControlWebsite at post-
test (t=−5.7, df= 13.0, p b 0.001) and 6 months (t=−2.8, df=5.8,
p = 0.031), and a signiﬁcant difference between Active and Control
websites at post-test (t=−3.1, df= 12.9, p= 0.009). Scores in the Ser-
traline group decreased from 14.8 (SD = 5.2) at baseline to 3.8 (SD =
2.8) at post-test and 5.5 (SD = 6.0) at 6 months. The effect was not sig-
niﬁcant relative to control at 12 months (n = 1). The Active Website
was associated with a drop from 11.5 (SD = 3.7) to 6.5 (SD = 2.3) at
post-test, 8.3 at 6 months (SD = 5.4) and 4.8 (SD = 4.6) at 12 months.
The effect of the Active Website was not signiﬁcantly different from the
Control Website at 6 and 12 month follow-up. Over 12 months the Con-
trol Website was associated with no change from the baseline mean of
11.7 (SD = 4.8) to the post-test mean of 12.0 (SD = 6.5), followed by a
small reduction to 8.3 (4.1) at 6 months and 5.3 (SE=3.2) at 12 months.
Planned contrasts between the Sertraline and Active Website groups re-
vealed a signiﬁcant difference of GAD-7 scores between these conditions
at post-test (t=−2.9, df= 13.0, p= 0.011), but not at 6 or 12 months
(p = 0.107 and 0.478 respectively). Fig. 2 takes into account attrition
under the missing data at random assumption, by presenting estimated
marginal means of GAD-7 scores from the mixed effects repeated mea-
sures model.
At post-test, among completers, a 20% reduction in anxiety symp-
toms was reached by 100% of participants in the Sertraline and Active
Website conditions but only 33% of Control Website participants
(χ2 = 8.9, df = 2, p = .012). DSM-IV criteria were only assessed in 8
of the participants at 6 months (3 Control, 4 Active, 1 Sertraline) using
the MINI. Of these, one Control and one Active participant still met the
criteria for current GAD. However, due to the small sample for which
DSM-IV criteria and symptom reduction data were available, it was
not possible to assess the full criteria for anxiety reduction as deﬁned
(i.e., 20% reduction and not meeting DSM-IV criteria).
3.4. Depression
CES-D scores also declined over the 12 month period (F= 26.6, df=
3, 7.3, p b 0.001). Therewas also a signiﬁcant overall interaction effect be-
tween condition and time (F= 3.7, df= 6, 8.3, p= 0.043). Speciﬁcally,
relative to the ControlWebsite, scores in the Sertraline condition reduced
signiﬁcantly at 6 months (t = −3.0, df = 11.5, p = 0.011) and
12 months (t=−2.4, df=6.9, p= 0.046) but not post-test. For Sertra-
line, scoreswere 37.0 (SD= 12.0), 19.7 (SD= 21.4), 16.0 (SD=5.6) and
6.0 (n = 1) respectively. Among those who received the Active Website,
scores were 23.4 (SD = 11.8), 17.7 (SD = 9.1), 20.8 (SD = 12.3) and
15.3 (SD = 13.4), respectively. The Control Website was associated
with mean scores of 27.1 (SD = 7.6), 23.8 (SD = 10.6), 20.0 (SD= 9.0)
and 16.5 (SD = 5.4) respectively. Fig. 3 takes into account attrition
under the missing data at random assumption, by presenting estimated
marginal means of CES-D scores from the mixed effects repeated mea-
sures model.
3.5. Effect sizes
Relative to the ControlWebsite condition at post-test, for GAD-7 and
CES-D respectively, the between group effect sizes were 2.43 and 0.68
for the Active Website condition, and 3.00 and 0.20 for the Sertraline
condition. The within group effect size for the Control Website from
baseline to post-test was−0.04 for GAD-7 and 0.31 for CES-D.
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Fig. 2. Estimated marginal means from the mixed effects repeated measures model of
GAD-7 scores as a function of group across measurement occasions.
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To our knowledge there are no registered randomised controlled tri-
als comparing an antidepressant treatment with an online psychologi-
cal intervention treatment for GAD. This trial is the ﬁrst to compare an
online Internet program with a gold standard pharmacological
treatment.
The trial found strong effect sizes for both the ActiveWebsite and for
the Sertraline for generalised anxiety symptoms as measured by the
GAD 7. These effects were signiﬁcant for Sertraline and the Active
Website at immediate post-test, but due to the small number of partic-
ipants, only Sertraline was still signiﬁcant at 6 months relative to con-
trol. In addition to anxiety symptoms, a large between groups effect
was found for depressive symptoms as measured by the CES-D at six
months and at 12 months for Sertraline. A small, non-signiﬁcant effect
was found for the Active Website at post-test.
The present study is an unusual treatment study, in that recruitment
to the trial was based on exclusion from a broader prevention trial,
which offered an “online intervention”. The trial itself was conducted
within a university based clinic, with face-to-face monitoring, and pa-
tientswere required to travel distances for treatment. The ﬁnal outcome
measures matched those in the prevention trial, and were undertaken
online through a central portal. As such, the trial has a number of impor-
tant limitations, and strengths. First, recruitment from the prevention
trial to the treatment trial was poor, with less than 14% of those referred
to the website from the prevention arm of the project actually entering
the trial. This resulted in a consequent reduction in power. However,0
5
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Sertraline
Fig. 3. CESD scores as a function of group across measurement occasions.even with this power, the effects were large enough to yield signiﬁcant
effects for the Sertraline and the Active Website condition relative to
Control. Importantly the effect sizes, which give an indication of the
size of the effect, were large for both the Sertraline condition and theAc-
tive Website. Clearly, both of these interventions were signiﬁcant.
We are unclear about why less than 14% of participants signed up to
the trial. This is likely due to a mismatch between their expectations
that treatment would be provided online, the burden required by the
face-to-face treatment protocol, the distances needed to travel, or the
negative effects of being “rejected” from the initial trial. In any case,
the generalisability of the ﬁndings will be limited. We have to conclude
that theﬁnal group recruited to this current trial, formed aminority pre-
pared to accept face-to-face treatment. Nevertheless, in terms of their
mental health proﬁle relative to other groups seeking help for GAD, all
met the criteria for GAD. Symptoms of GAD at baseline indicated that
they were in the top 0.8% of the population, and that they represented
a comparable clinical group to others used in Sertraline and face-to-
face treatment trials.
Another limitation of the trial was the potential of selective bias in
the ﬁndings because of differential dropout, although the dropout rate
did not differ signiﬁcantly. It is not clearwhy the ControlWebsite partic-
ipants did not improve once they were provided with the Active
Website at post-test. This may be due to the fact that increased wait
times decrease treatment effectiveness, or that participants sought inef-
fective interventions elsewhere. Due to the number of clinicians and re-
search staff involved, the implementation of trial protocol may not have
been uniform over the course of recruitment, which spanned two years.
Finally, despite the recent recognition of the importance of negative ef-
fects (Rozental et al., 2014), it was not possible tomeaningfully examine
these outcomes, another limitation of the small sample size.
The trial did have a number of strengths. First, the clinical outcomes
used in the trial were all collected in an automated fashion, via the web
portal, increasing level of blinding. The original samplewas recruited via
the Electoral Roll, so participants may have included those who would
not normally seek treatment, and thus may have represented those
with ‘unmet need’, and indeed, may have represented a group who
were reluctant to seek treatment.
Although small, the study suggests that GAD is responsive to both
online treatment and Sertraline, a ﬁnding that requires extension and
replication. The outcomes of the present trial are relevant to the practi-
cal management of GAD in primary care. GAD treatment using an e-
health application with minimal therapist input appears to be effective,
and as such, offers an alternative to medication, and may be a preferred
treatment. Given the shortage of qualiﬁed therapists, escalating health
costs, and the low rates of treatment seeking in those with amental dis-
order (Wittchen, 2000), theseﬁndings have important clinical andprac-
tical implications. There is also evidence emerging that CBT in
combinationwith an SSRImay be helpful in general practice for patients
with treatment resistant depression (Wiles et al., 2013), suggesting a
possible area of further investigation.
From a research perspective, it has been questioned whether online
patients are as severe or incapacitated as ofﬂine patients. This study
goes someway to conﬁrming that these patient groups comprise similar
clinical proﬁles, and also that for some, online treatment may be pre-
ferred to medication in a GP setting.
The effect sizes reported for the GAD effects in this studywere large.
Many online programs do not report within-group effects of such mag-
nitude. The effects of Sertraline are often reported to bemuch less. There
are a number of possible explanations for the size of these effects. First,
the Active Website and Sertraline were offered in the context of best
practice treatment, with regular follow-up by psychologists and GPs.
Second, by the time participants reached the treatment stage of the
trial, and were enrolled in it, their commitment and motivation were
likely to be high. An additional observation is that the provision of GP
and psychologist support alone was not effective, given the very weak
effects observed in the Control Website condition.
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